CRISPR Technology: Global Markets
CRISPR Technology: Global Markets
Abstract
Report Scope:
The current report provides detailed exposure to the CRISPR technology market. This report highlights the current and future market potential of CRISPR technology, along with a detailed analysis of the drivers, restraints, and challenges in the market. The report also covers market projections for 2027, as well as the competitive environment and regulatory scenario. The report details the market share of CRISPR technology on applications and end users. The market is segmented into Biotechnology & Pharmaceutical Companies, Academics & Government Research Institutes, and Contract Research Organizations (CROs) based on end users. The market is categorized as Drug Development, Agriculture, Diagnostics, Clinical therapy, and Others based on Application. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also discusses the impact of the COVID-19 pandemic on this market.
By geography, the market has been segregated into North America, Europe, Asia-Pacific, and the Rest of the world. The North American region includes countries such as the U.S. and Canada; Europe includes Germany, U.K., France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2019 as the historic year, 2021 as the base year, and forecast for 2027.
Report Includes:
- 17 data tables and 37 additional tables
- An up-to-date overview and analysis of the global market for CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology
- Analyses of the global market trends, with historic revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the market potential for CRISPR technology, industry growth drivers, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of the actual market size and revenue forecast for the global CRISPR technology market in USD million terms, and corresponding market share analysis by application, end user, and region
- Discussion of the major market dynamics, key shifts and regulations, industry specific challenges, and macroeconomic factors affecting the demand for CRISPR technology market over the coming years (2022-2027)
- Identification of the companies that are best positioned to meet this demand because of their proprietary technologies, strategic alliances, or other advantages
- A look at the recent technical breakthrough on the use of CRISPR-Cas9 genome editing technology, and how it has propelled the rapid growth in genetic engineering and advanced pharmacological research
- Comparative study on CRISPR with TALE and ZFN nuclease as a gene editing tool and discussion on its higher adaptability over other nucleases
- Review of the patent filings and research publications for innovations in the CRISPR-Cas9 genome editing technology
- Insight into recent industry structure for CRISPR-Cas9 genome editing technology, competitive environment, clinical trials, ongoing research activities, and the COVID-19 impact on the marketplace
- Company profiles of major players within the industry, including CRISPR Therapeutics AG, GenScript, Lonza Group Ltd, PerkinElmer and Thermo Fisher Scientific Inc.
Content
Table of Contents
Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing This Study
1.3 Intended Audience
1.4 Scope of Report
1.5 What's New in this Report?
1.6 Information Sources
1.7 Methodology
1.8 Geographic Breakdown
1.9 Analyst's Credentials
1.10 BCC Custom Research
1.11 Related BCC Research Reports
Chapter 2 Summary and Highlights
2.1 Highlights of the Market for CRISPR Technology
Chapter 3 Market Overview
3.1 CRISPR: Genetic Editing
3.2 Components of CRISPR-Cas Systems
3.2.1 SgRNA
3.2.2 Cas9 Nucleases
3.3 How CRISPR-Cas Works?
3.4 Advantage of the CRISPR-Cas9 System
3.5 Popularity of CRISPR Genome Editing
3.6 Pros of Genetic Editing
3.7 CRISPR Development Phases
3.7.1 Discovery of CRISPR
3.7.2 Discovery of Cas9 and PAM
3.7.3 Hypothesis: Adaptive Immunity
3.7.4 Adaptive Immunity
3.7.5 Spacer Sequences: gRNAs
3.7.6 CRISPR Acts on DNA Targets
3.7.7 Cas9 Cleaves Target DNA
3.7.8 tracrRNA for Cas9 Systems
3.7.9 CRISPR Systems in Other Species
3.7.10 Cas9-Mediated Cleavage
3.7.11 CRISPR-Cas9: Genome Editing
3.8 Market Potential
3.9 Regulatory Framework
3.9.1 U.S. Regulation and Oversight
3.9.2 NIH Guidelines
3.9.3 U.S. FDA
3.9.4 Regulatory Issues
3.9.5 Regulations of Human Germline Edits
3.9.6 Global Regulations
3.10 Porter's Five Forces Analysis of the Market for CRISPR Technology
3.10.1 Bargaining Power of Suppliers: Low
3.10.2 Bargaining Power of Buyers: Moderate
3.10.3 The Threat of Substitutes: Moderate
3.10.4 The Threat of New Entrants: Moderate
3.10.5 The Intensity of Competitive Rivalry: Low
3.11 Scientific Publications
3.12 Patent Analysis
3.12.1 Overview of CRISPR Technology Intellectual Property (IP) and Licensing Structure
3.13 Future of CRISPR
3.14 Market Drivers
3.14.1 CRISPR Versus Chronic Disease
3.14.2 High Prevalence of Genetic Disorders
3.14.3 Government and Private Funding
3.14.4 Increasing Applications of CRISPR
3.15 Market Restraints
3.15.1 Alternative Technologies
3.15.2 Off-target Activity
3.16 Market Challenges
3.16.1 Patent Issues
3.16.2 Risks Associated with CRISPR
3.16.3 R&D
3.16.4 Governmental Policies and Regulations
3.16.5 Bioethical Issues
Chapter 4 Industry Structure
4.1 Commercial Therapeutics
4.2 Correcting Genetic Errors
4.3 Microbes
4.4 Healthier Food
Chapter 5 Impact of COVID-19 on the Market for CRISPR Technology
5.1 Overview
Chapter 6 Competitive Landscape
6.1 Overview
6.2 Competitive Scenario
6.3 Beam Therapeutics
6.4 CRISPR Therapeutics
6.5 Editas Medicine
6.6 Intellia Therapeutics
6.7 Growth Strategies
6.7.1 Licensing and Agreements
6.7.2 Collaborations With Big Biopharmaceutical Companies
6.7.3 Mergers and Acquisitions
Chapter 7 Global Market for CRISPR Technology by End User
7.1 Market Overview
7.2 Market Share and Forecast
7.3 Biotechnology and Pharmaceutical Companies
7.4 Academics and Government Research Institutes
7.5 Contract Research Organizations
Chapter 8 Global Market for CRISPR Technology by Application
8.1 Market Share and Forecast
8.2 Drug Development
8.3 Agriculture
8.4 Diagnostics
8.4.1 Infectious Diseases
8.4.2 Non-infectious diseases
8.5 Clinical Therapy
8.6 Others
Chapter 9 Global Market for CRISPR Technology by Region
9.1 North America
9.1.1 U.S.
9.1.2 Canada
9.2 Europe
9.2.1 Germany
9.2.2 United Kingdom
9.2.3 France
9.2.4 Rest of Europe
9.3 Asia-Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Rest of Asia-Pacific
9.4 Rest of the World
Chapter 10 Company Profiles
CARIBOU BIOSCIENCES
CRISPR THERAPEUTICS AG
DANAHER CORP.
EDITAS MEDICINE
GENSCRIPT
HERA BIOLABS
INTELLIA THERAPEUTICS INC.
LONZA GROUP LTD.
MAMMOTH BIOSCIENCES INC.
NEW ENGLAND BIOLABS INC.
ORIGENE TECHNOLOGIES
PERKINELMER
PRECISION BIOSCIENCES
SYNTHEGO
THERMO FISHER SCIENTIFIC
TOOLGEN INC.
List of Tables
Summary Table B : Global Market for CRISPR Technology, by Region, Through 2027
Summary Table A : Global Market for CRISPR Technology, by End User, Through 2027
Table 1 : Comparison of Genome Editing Technologies
Table 2 : Selected Monogenic Disease Details
Table 3 : CRISPR Applications
Table 4 : Global Incidence of Cancer, by Cancer Type/Site, 2020
Table 5 : Venture Capitalist Funding, by Company in Gene Editing
Table 6 : Bioethical Issues and Risks Associated with CRISPR Technology
Table 7 : Selected CAR-T/Gene-Editing Collaborations
Table 8 : CRISPR Technology: Competitive Scenario
Table 9 : CRISPR Technology: Selected Companies
Table 10 : Global Market for CRISPR Technology, by End User, Through 2027
Table 11 : Collaborations among Biotechnology and Pharmaceutical CRISPR Technology Companies
Table 12 : Global Market for CRISPR Technology in Biotechnology and Pharmaceutical End Uses, by Region, Through 2027
Table 13 : Companies Licensing CRISPR Technology from Research Institutions
Table 14 : Global Market for CRISPR Technology in Academic and Government Research Institute End Uses, by Region, Through 2027
Table 15 : Global Market for CRISPR Technology in Contract Research Organization End Uses, by Region, Through 2027
Table 16 : Global Market for CRISPR Technology, by Application, Through 2027
Table 17 : Global Market for Drug Development Applications of CRISPR Technology, by Region, Through 2027
Table 18 : CRISPR: Edited Crops
Table 19 : Global Market for Agriculture-Based Applications of CRISPR Technology, by Region, Through 2027
Table 20 : Global Market for Diagnostic Applications of CRISPR Technology, by Region, Through 2027
Table 21 : Clinical Trial Using CRISPR Technology for Chronic Disease
Table 22 : Global Market for Clinical Therapeutic Applications of CRISPR Technology, by Region, Through 2027
Table 23 : Global Market for Other Applications of CRISPR Technology, by Region, Through 2027
Table 24 : Global Market for CRISPR Technology, by Region, Through 2027
Table 25 : European Market for CRISPR Technology, by Country, Through 2027
Table 26 : Asia-Pacific Market for CRISPR Technology, by Country, Through 2027
Table 27 : Caribou Biosciences: Product Portfolio
Table 28 : Caribou Biosciences: Recent Developments, 2021
Table 29 : CRISPR Therapeutics AG: Product Portfolio
Table 30 : CRISPR Therapeutics AG: Recent Developments, 2021 and 2022
Table 31 : Danaher: Product Portfolio
Table 32 : Danaher: Recent Developments, 2020 and 2021
Table 33 : Editas Medicine: Product Portfolio
Table 34 : Editas Medicine: Recent Developments, 2020-2022
Table 35 : GenScript: Product Portfolio
Table 36 : GenScript: Recent Developments, 2020 and 2021
Table 37 : Hera Biolabs: Product Portfolio
Table 38 : Hera Biolabs: Recent Developments, 2020 and 2021
Table 39 : Intellia Therapeutics Inc.: Product Portfolio
Table 40 : Intellia Therapeutics Inc.: Recent Developments, 2020-2022
Table 41 : Lonza Group Ltd.: Product Portfolio
Table 42 : Lonza Group Ltd.: Recent Developments, 2020 and 2021
Table 43 : Mammoth Biosciences Inc.: Recent Developments, 2020-2022
Table 44 : New England Biolabs Inc.: Product Portfolio
Table 45 : New England Biolabs Inc.: Recent Developments, 2020 and 2021
Table 46 : OriGene Technologies: Product Portfolio
Table 47 : PerkinElmer: Product Portfolio
Table 48 : PerkinElmer: Recent Developments, 2020 and 2021
Table 49 : Precision BioSciences: Product Portfolio
Table 50 : Precision BioSciences: Recent Developments, 2020-2022
Table 51 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 52 : Thermo Fisher Scientific Inc.: Recent Developments, 2020-2022
The current report provides detailed exposure to the CRISPR technology market. This report highlights the current and future market potential of CRISPR technology, along with a detailed analysis of the drivers, restraints, and challenges in the market. The report also covers market projections for 2027, as well as the competitive environment and regulatory scenario. The report details the market share of CRISPR technology on applications and end users. The market is segmented into Biotechnology & Pharmaceutical Companies, Academics & Government Research Institutes, and Contract Research Organizations (CROs) based on end users. The market is categorized as Drug Development, Agriculture, Diagnostics, Clinical therapy, and Others based on Application. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also discusses the impact of the COVID-19 pandemic on this market.
By geography, the market has been segregated into North America, Europe, Asia-Pacific, and the Rest of the world. The North American region includes countries such as the U.S. and Canada; Europe includes Germany, U.K., France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2019 as the historic year, 2021 as the base year, and forecast for 2027.
Report Includes:
- 17 data tables and 37 additional tables
- An up-to-date overview and analysis of the global market for CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology
- Analyses of the global market trends, with historic revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the market potential for CRISPR technology, industry growth drivers, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of the actual market size and revenue forecast for the global CRISPR technology market in USD million terms, and corresponding market share analysis by application, end user, and region
- Discussion of the major market dynamics, key shifts and regulations, industry specific challenges, and macroeconomic factors affecting the demand for CRISPR technology market over the coming years (2022-2027)
- Identification of the companies that are best positioned to meet this demand because of their proprietary technologies, strategic alliances, or other advantages
- A look at the recent technical breakthrough on the use of CRISPR-Cas9 genome editing technology, and how it has propelled the rapid growth in genetic engineering and advanced pharmacological research
- Comparative study on CRISPR with TALE and ZFN nuclease as a gene editing tool and discussion on its higher adaptability over other nucleases
- Review of the patent filings and research publications for innovations in the CRISPR-Cas9 genome editing technology
- Insight into recent industry structure for CRISPR-Cas9 genome editing technology, competitive environment, clinical trials, ongoing research activities, and the COVID-19 impact on the marketplace
- Company profiles of major players within the industry, including CRISPR Therapeutics AG, GenScript, Lonza Group Ltd, PerkinElmer and Thermo Fisher Scientific Inc.
Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing This Study
1.3 Intended Audience
1.4 Scope of Report
1.5 What's New in this Report?
1.6 Information Sources
1.7 Methodology
1.8 Geographic Breakdown
1.9 Analyst's Credentials
1.10 BCC Custom Research
1.11 Related BCC Research Reports
Chapter 2 Summary and Highlights
2.1 Highlights of the Market for CRISPR Technology
Chapter 3 Market Overview
3.1 CRISPR: Genetic Editing
3.2 Components of CRISPR-Cas Systems
3.2.1 SgRNA
3.2.2 Cas9 Nucleases
3.3 How CRISPR-Cas Works?
3.4 Advantage of the CRISPR-Cas9 System
3.5 Popularity of CRISPR Genome Editing
3.6 Pros of Genetic Editing
3.7 CRISPR Development Phases
3.7.1 Discovery of CRISPR
3.7.2 Discovery of Cas9 and PAM
3.7.3 Hypothesis: Adaptive Immunity
3.7.4 Adaptive Immunity
3.7.5 Spacer Sequences: gRNAs
3.7.6 CRISPR Acts on DNA Targets
3.7.7 Cas9 Cleaves Target DNA
3.7.8 tracrRNA for Cas9 Systems
3.7.9 CRISPR Systems in Other Species
3.7.10 Cas9-Mediated Cleavage
3.7.11 CRISPR-Cas9: Genome Editing
3.8 Market Potential
3.9 Regulatory Framework
3.9.1 U.S. Regulation and Oversight
3.9.2 NIH Guidelines
3.9.3 U.S. FDA
3.9.4 Regulatory Issues
3.9.5 Regulations of Human Germline Edits
3.9.6 Global Regulations
3.10 Porter's Five Forces Analysis of the Market for CRISPR Technology
3.10.1 Bargaining Power of Suppliers: Low
3.10.2 Bargaining Power of Buyers: Moderate
3.10.3 The Threat of Substitutes: Moderate
3.10.4 The Threat of New Entrants: Moderate
3.10.5 The Intensity of Competitive Rivalry: Low
3.11 Scientific Publications
3.12 Patent Analysis
3.12.1 Overview of CRISPR Technology Intellectual Property (IP) and Licensing Structure
3.13 Future of CRISPR
3.14 Market Drivers
3.14.1 CRISPR Versus Chronic Disease
3.14.2 High Prevalence of Genetic Disorders
3.14.3 Government and Private Funding
3.14.4 Increasing Applications of CRISPR
3.15 Market Restraints
3.15.1 Alternative Technologies
3.15.2 Off-target Activity
3.16 Market Challenges
3.16.1 Patent Issues
3.16.2 Risks Associated with CRISPR
3.16.3 R&D
3.16.4 Governmental Policies and Regulations
3.16.5 Bioethical Issues
Chapter 4 Industry Structure
4.1 Commercial Therapeutics
4.2 Correcting Genetic Errors
4.3 Microbes
4.4 Healthier Food
Chapter 5 Impact of COVID-19 on the Market for CRISPR Technology
5.1 Overview
Chapter 6 Competitive Landscape
6.1 Overview
6.2 Competitive Scenario
6.3 Beam Therapeutics
6.4 CRISPR Therapeutics
6.5 Editas Medicine
6.6 Intellia Therapeutics
6.7 Growth Strategies
6.7.1 Licensing and Agreements
6.7.2 Collaborations With Big Biopharmaceutical Companies
6.7.3 Mergers and Acquisitions
Chapter 7 Global Market for CRISPR Technology by End User
7.1 Market Overview
7.2 Market Share and Forecast
7.3 Biotechnology and Pharmaceutical Companies
7.4 Academics and Government Research Institutes
7.5 Contract Research Organizations
Chapter 8 Global Market for CRISPR Technology by Application
8.1 Market Share and Forecast
8.2 Drug Development
8.3 Agriculture
8.4 Diagnostics
8.4.1 Infectious Diseases
8.4.2 Non-infectious diseases
8.5 Clinical Therapy
8.6 Others
Chapter 9 Global Market for CRISPR Technology by Region
9.1 North America
9.1.1 U.S.
9.1.2 Canada
9.2 Europe
9.2.1 Germany
9.2.2 United Kingdom
9.2.3 France
9.2.4 Rest of Europe
9.3 Asia-Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Rest of Asia-Pacific
9.4 Rest of the World
Chapter 10 Company Profiles
CARIBOU BIOSCIENCES
CRISPR THERAPEUTICS AG
DANAHER CORP.
EDITAS MEDICINE
GENSCRIPT
HERA BIOLABS
INTELLIA THERAPEUTICS INC.
LONZA GROUP LTD.
MAMMOTH BIOSCIENCES INC.
NEW ENGLAND BIOLABS INC.
ORIGENE TECHNOLOGIES
PERKINELMER
PRECISION BIOSCIENCES
SYNTHEGO
THERMO FISHER SCIENTIFIC
TOOLGEN INC.
List of Tables
Summary Table B : Global Market for CRISPR Technology, by Region, Through 2027
Summary Table A : Global Market for CRISPR Technology, by End User, Through 2027
Table 1 : Comparison of Genome Editing Technologies
Table 2 : Selected Monogenic Disease Details
Table 3 : CRISPR Applications
Table 4 : Global Incidence of Cancer, by Cancer Type/Site, 2020
Table 5 : Venture Capitalist Funding, by Company in Gene Editing
Table 6 : Bioethical Issues and Risks Associated with CRISPR Technology
Table 7 : Selected CAR-T/Gene-Editing Collaborations
Table 8 : CRISPR Technology: Competitive Scenario
Table 9 : CRISPR Technology: Selected Companies
Table 10 : Global Market for CRISPR Technology, by End User, Through 2027
Table 11 : Collaborations among Biotechnology and Pharmaceutical CRISPR Technology Companies
Table 12 : Global Market for CRISPR Technology in Biotechnology and Pharmaceutical End Uses, by Region, Through 2027
Table 13 : Companies Licensing CRISPR Technology from Research Institutions
Table 14 : Global Market for CRISPR Technology in Academic and Government Research Institute End Uses, by Region, Through 2027
Table 15 : Global Market for CRISPR Technology in Contract Research Organization End Uses, by Region, Through 2027
Table 16 : Global Market for CRISPR Technology, by Application, Through 2027
Table 17 : Global Market for Drug Development Applications of CRISPR Technology, by Region, Through 2027
Table 18 : CRISPR: Edited Crops
Table 19 : Global Market for Agriculture-Based Applications of CRISPR Technology, by Region, Through 2027
Table 20 : Global Market for Diagnostic Applications of CRISPR Technology, by Region, Through 2027
Table 21 : Clinical Trial Using CRISPR Technology for Chronic Disease
Table 22 : Global Market for Clinical Therapeutic Applications of CRISPR Technology, by Region, Through 2027
Table 23 : Global Market for Other Applications of CRISPR Technology, by Region, Through 2027
Table 24 : Global Market for CRISPR Technology, by Region, Through 2027
Table 25 : European Market for CRISPR Technology, by Country, Through 2027
Table 26 : Asia-Pacific Market for CRISPR Technology, by Country, Through 2027
Table 27 : Caribou Biosciences: Product Portfolio
Table 28 : Caribou Biosciences: Recent Developments, 2021
Table 29 : CRISPR Therapeutics AG: Product Portfolio
Table 30 : CRISPR Therapeutics AG: Recent Developments, 2021 and 2022
Table 31 : Danaher: Product Portfolio
Table 32 : Danaher: Recent Developments, 2020 and 2021
Table 33 : Editas Medicine: Product Portfolio
Table 34 : Editas Medicine: Recent Developments, 2020-2022
Table 35 : GenScript: Product Portfolio
Table 36 : GenScript: Recent Developments, 2020 and 2021
Table 37 : Hera Biolabs: Product Portfolio
Table 38 : Hera Biolabs: Recent Developments, 2020 and 2021
Table 39 : Intellia Therapeutics Inc.: Product Portfolio
Table 40 : Intellia Therapeutics Inc.: Recent Developments, 2020-2022
Table 41 : Lonza Group Ltd.: Product Portfolio
Table 42 : Lonza Group Ltd.: Recent Developments, 2020 and 2021
Table 43 : Mammoth Biosciences Inc.: Recent Developments, 2020-2022
Table 44 : New England Biolabs Inc.: Product Portfolio
Table 45 : New England Biolabs Inc.: Recent Developments, 2020 and 2021
Table 46 : OriGene Technologies: Product Portfolio
Table 47 : PerkinElmer: Product Portfolio
Table 48 : PerkinElmer: Recent Developments, 2020 and 2021
Table 49 : Precision BioSciences: Product Portfolio
Table 50 : Precision BioSciences: Recent Developments, 2020-2022
Table 51 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 52 : Thermo Fisher Scientific Inc.: Recent Developments, 2020-2022
Related Report
